The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 29, 2014
Filed:
Oct. 18, 2007
Andrew David Abell, Christchurch, NZ;
James Morriss Coxon, Christchurch, NZ;
Matthew Alan Jones, Christchurch, NZ;
Stephen Brian Mcnabb, Christchurch, NZ;
Axel Thomas Neffe, Christchurch, NZ;
Steven Geoffrey Aitken, Christchurch, NZ;
Blair Gibb Stuart, Christchurch, NZ;
Janna Marie Nikkel, Christchurch, NZ;
Joanna Kimberley Duncan, Christchurch, NZ;
Mutita Klanchantra, Christchurch, NZ;
James David Morton, Canterbury, NZ;
Roy Bickerstaffe, Canterbury, NZ;
Lucinda Jane Goodricke Robertson, Canterbury, NZ;
Hannah Yun Young Lee, Christchurch, NZ;
Matthew Stewart Muir, Canterbury, NZ;
Andrew David Abell, Christchurch, NZ;
James Morriss Coxon, Christchurch, NZ;
Matthew Alan Jones, Christchurch, NZ;
Stephen Brian McNabb, Christchurch, NZ;
Axel Thomas Neffe, Christchurch, NZ;
Steven Geoffrey Aitken, Christchurch, NZ;
Blair Gibb Stuart, Christchurch, NZ;
Janna Marie Nikkel, Christchurch, NZ;
Joanna Kimberley Duncan, Christchurch, NZ;
Mutita Klanchantra, Christchurch, NZ;
James David Morton, Canterbury, NZ;
Roy Bickerstaffe, Canterbury, NZ;
Lucinda Jane Goodricke Robertson, Canterbury, NZ;
Hannah Yun Young Lee, Christchurch, NZ;
Matthew Stewart Muir, Canterbury, NZ;
Lincoln University, Lincoln, Canterbury, NZ;
Canterprise Limited, Christchurch, NZ;
Douglas Pharmaceuticals Limited, Henderson Auckland, NZ;
Abstract
The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity.